[1] |
Fiboumi AE, Chiheb S. Impetigo herpetiformis: a rare dermotosis of pregnancy[J]. Pan Afr Med J, 2018,30:273. doi: 10.11604/pamj.2018.30.273.16424.
|
[2] |
Tejeda CI, Voss V, Salvemini JN. Known history of pustular psoriasis with reactivation from in vitro fertilization therapy[J]. JAAD Case Rep, 2019,5(6):543⁃545. doi: 10.1016/j.jdcr.2019. 04.005.
|
[3] |
Namazi N, Dadkhahfar S. Impetigoherpetiformis: review of pathogenesis, complication, and treatment[J]. Dermatol Res Pract, 2018,2018:5801280. doi: 10.1155/2018/5801280.
|
[4] |
Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives[J]. Int J Womens Health, 2018,10:109⁃115. doi: 10.2147/IJWH.S125784.
|
[5] |
Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment[J]. J Eur Acad Dermatol Venereol, 2018,32(10):1645⁃1651. doi: 10.1111/jdv. 14949.
|
[6] |
Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2012,67(2):279⁃288. doi: 10.1016/j.jaad.2011.01.032.
|
[7] |
Chhabra G, Chanana C, Verma P, et al. Impetigo herpetiformis responsive to secukinumab[J]. Dermatol Ther, 2019,32(5):e13040. doi: 10.1111/dth.13040.
|
[8] |
Yamashita T, Hamada T, Maruta Y, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare⁃up[J]. Int J Dermatol, 2019,58(3):350⁃353. doi: 10.1111/ijd.14141.
|
[9] |
Ogrum A, Takci Z, Seckin HY, et al. Treatment resistant impetigo herpetiformis treated with infliximab[J]. Dermatol Ther, 2019,32(2):e12839. doi: 10.1111/dth.12839.
|
[10] |
Babuna Kobaner G, PolatEkinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: report of a challenging case[J]. Dermatol Ther, 2020,33(4):e13571. doi: 10.1111/dth.13571.
|
[11] |
Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long⁃term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis[J]. Ann Rheum Dis, 2017,76(2):414⁃417. doi: 10.1136/annrheumdis⁃2016⁃209322.
|
[12] |
Flynn A, Burke N, Byrne B, et al. Two case reports of generalized pustular psoriasis of pregnancy: different outcomes[J]. Obstet Med, 2016,9(2):55⁃59. doi: 10.1177/1753495X15626623.
|
[13] |
Gordon KB, Warren RB, Gottlieb AB, et al. Long⁃term efficacy of certolizumabpegol for the treatment of plaque psoriasis: 3⁃year results from two randomized phase Ⅲ trials (CIMPASI⁃1 and CIMPASI⁃2)[J]. Br J Dermatol, 2020. doi: 10.1111/bjd.19393.
|
[14] |
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study[J]. Ann Rheum Dis, 2018,77(2):228⁃233. doi: 10.1136/annrheumdis⁃ 2017⁃212196.
|
[15] |
Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report[J]. Acta Derm Venereol, 2020,100(15):adv00251. doi: 10.2340/ 00015555⁃3611.
|
[16] |
Mizutani Y, Mizutani YH, Matsuyama K, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumabpegol[J]. J Dermatol, 2020,47(7):e262⁃e263. doi: 10.1111/1346⁃8138.15355.
|
[17] |
Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database[J]. Br J Dermatol, 2018,179(5):1205⁃1207. doi: 10.1111/bjd.16901.
|
[18] |
Kinoshita M, Ogawa Y, Takeichi T, et al. Impetigo herpetiformis with IL⁃36RN mutation successfully treated with secukinumab[J]. Eur J Dermatol, 2018,28(3):381⁃382. doi: 10.1684/ejd. 2018.3259.
|
[19] |
Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis[J]. J Eur Acad Dermatol Venereol, 2016,30(3):488⁃490. doi: 10.1111/jdv.12872.
|
[20] |
Mizutani Y, Fujii K, Kawamura M, et al. Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis[J]. J Dermatol, 2020,47(11):1326⁃1329. doi: 10.1111/1346⁃8138.15569.
|
[21] |
Fujii K, Takahashi T, Matsuyama K, et al. Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis[J]. J Dermatol, 2020,47(3):e84⁃e85. doi: 10.1111/1346⁃8138.15241.
|
[22] |
Saito⁃Sasaki N, Izu K, Sawada Y, et al. Impetigo herpetiformis complicated with intrauterine growth restriction treated successfully with granulocyte and monocyte apheresis[J]. Acta Derm Venereol, 2017,97(3):410⁃411. doi: 10.2340/00015555⁃2527.
|
[23] |
Luewan S, Sirichotiyakul S, Tongsong T. Recurrent impetigo herpetiformis successfully treated with methotrexate: a case report[J]. J ObstetGynaecol Res, 2011,37(6):661⁃663. doi: 10. 1111/j.1447⁃0756.2010.01418.x.
|
[24] |
Cravo M, Vieira R, Tellechea O, et al. Recurrent impetigo herpetiformis successfully treated with methotrexate[J]. J Eur Acad Dermatol Venereol, 2009,23(3):336⁃337. doi: 10.1111/j.1468⁃3083.2008.02867.x.
|